RAD51D mutations are common somatic mutations in mesothelioma [33], and somatic RAD51D mutation is an inclusion criterion in phase 2 clinical trial for mesothelioma and is believed to predict poly ADP ribose polymerase (PARP) inhibitor sensitivity (https://ichgcp.net/clinical-trials-registry/NCT04171700) (accessed on 24 August 2021). The gene discussed is RAD51D; the disease is mesothelioma.